TD Cowen analyst Ritu Baral maintained a Buy rating on Inventiva (IVA – Research Report) today. The company’s shares closed yesterday at ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...

TD Cowen analyst Ritu Baral provided insights from a key opinion leader (KOL) in orphan neuromuscular diseases, who spoke at an investor event hosted by the Muscular Dystrophy Association (MDA).

Jefferies equity analyst Andrew Tsai and Ritu Baral, a managing director and senior biotech analyst with TD Cowen, both observed. Elevidys is indicated for individuals at least four years old to ...

“We believe the urgent heart failure language could give Alnylam an advantage,” Ritu Baral, an analyst at TD Cowen, said, “especially for front-line use.” ...

Hi, guys. Thanks for taking my question. This is Athena Chin on for Ritu Baral. I have a question on 720. As you see it now, what are the potential paths forward for 720? And when can we expect an ...

Operator: Thank you. [Operator Instructions]. And your first question comes from the line of Ritu Baral from TD Cowen. Please go ahead. Unidentified Analyst : Hi, everyone this is Nicole online ...

Update 10.28 AM EST: Adds latest share price move and comments from analysts Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the ...